Efient ®, awarded best pharmaceutical 2010 initiative.

The award ceremony took place yesterday in the theatres of the channel.

-The jury of awards granted by mail pharmacist believes that this drug indicated for patients with acute Coronario syndrome who have undergone a percutaneous coronary intervention, is one of the best initiatives of the year in the category of research, pharmacology, and product ”.

Madrid, March of 2011. Efient ® (prasugrel), marketed by Daiichi Sankyo and Lilly, NATO has been awarded by mail pharmacist as best pharmaceutical initiative of 2010 in the section on “Research, Pharmacology and products”.

Immaculate Gil Rabadán, CEO of Daiichi Sankyo and Lilly Marketing Manager Diego Guinea were responsible for collecting the award at the ceremony yesterday in the theatres of the Canal (Madrid).

this award recognizes the contribution Efient ® (prasugrel) for the treatment of patients with acute coronary syndrome (SCA) undergoing percutaneous coronary intervention (PCI) or angioplasty, with or without stent placement, since that is an alternative to standard treatment with clopidogrel – unique in the market for more than 10 years – and an increase in expectations of rehabilitation for these patients.

The results of the comprehensive study TRITON TIMI 38, developed with a sample of 13.608 patients, showed that Efient ®, compared with clopidogrel, reduced by 19% the risk of cardiovascular death, myocardial infarction or stroke, and 50% the risk of thrombosis by stent in patients with SCA, a PKI.